R&D Trends

CEOi, Sage Bionetworks, DREAM Project launch Alzheimer’s big data challenge

Wednesday, June 4, 2014 01:19 PM

The Global CEO Initiative on Alzheimer’s disease (CEOi), nonprofit biomedical research organization Sage Bionetworks and the DREAM Project have launched the Alzheimer’s Disease Big Data DREAM Challenge #1, in an effort to advance diagnostic innovation and identify new Alzheimer’s disease biomarkers through the use of open source data.

More... »

WIRB Copernicus Group

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner

Tuesday, June 3, 2014 01:23 PM

Memorial Sloan Kettering (MSK) Cancer Center and Quest Diagnostics, a provider of diagnostic information services, have formed a joint collaboration that will utilize MSK's clinical and research insights into gene mutations associated with solid tumors.

More... »

CRF Health eCOA webinar series

Qiagen, Eli Lilly collaborate to co-develop companion diagnostics

Tuesday, June 3, 2014 11:17 AM

Qiagen, a Netherlands-based holding company, is collaborating with Eli Lilly to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The agreement includes the development of tests that will be based on Qiagen's multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.   

More... »

Dako, Merck to collaborate on companion diagnostic test

Tuesday, June 3, 2014 10:15 AM

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, is collaborating with Merck to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer.

More... »

Aduro inks agreement with Janssen Biotech for prostate cancer candidates

Friday, May 30, 2014 01:39 PM

Aduro BioTech, a clinical-stage biotechnology company, has entered into an agreement granting Janssen Biotechan exclusive worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. The agreement is facilitated by the Johnson & Johnson Innovation center in California. Aduro is eligible to receive up to $365 million in upfront license fees and milestone payments upon achievement of defined development, regulatory and commercialization milestones, if multiple programs advance to commercialization, as well as tiered royalties on worldwide net sales.

More... »

Sangamo BioSciences, City of Hope granted $5.6M from CIRM

Friday, May 30, 2014 01:36 PM

The California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP therapeutic for HIV/AIDS based on the application of SangamoBioSciences' zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs).

More... »

Agenda-setting plan issued to accelerate cancer research, biomedical discovery

Friday, May 30, 2014 01:34 PM

The National Patient Advocate Foundation (NPAF), a nonprofit organization providing the patient's voice in improving access to quality cancer care, has released a blueprint to accelerate the delivery of new treatments to patients and launched a new grassroots movement called Project Innovation to drive action.

More... »

Oncothyreon, Celldex Therapeutics collaborate

Thursday, May 29, 2014 01:03 PM

Oncothyreon, a biotechnology company developing therapeutic products for the treatment of cancer, and Celldex Therapeutics have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab.

More... »

The Michael J. Fox Foundation, AbbVie launch Partners in Parkinson's

Wednesday, May 28, 2014 01:06 PM

The Michael J. Fox Foundation (MJFF) and AbbViehave launched Partners in Parkinson's, a new strategic health initiative offering comprehensive support to help people with Parkinson's disease (PD) optimize their care at every stage of the disease.

More... »

Macrogenics, Takeda ink agreement for autoimmune disorders

Wednesday, May 28, 2014 01:04 PM

MacroGenics, a clinical-stage biopharmaceutical company discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, and Takeda Pharmaceutical have entered into an agreement for the development and commercialization of MGD010.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs